ArticleJAAD case reports2023
Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus.
Article in JAAD case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06285435 (Activation of Coagulation as an Indicator of a Pro-thrombotic State in Patients With Pemphigus), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Activation of Coagulation as an Indicator of a Pro-thrombotic State in Patients With Pemphigus: A Case-control Study
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Biomarkers in Pemphigus Vulgaris: A Systematic Review.Journal of cutaneous medicine and surgeryPooled it
- Pemphigus herpetiformis: A case report of response to dupilumab after failure of multiple conventional therapies.JAAD case reports · 2026Article
- Case Report: Dupilumab as a corticosteroid-sparing adjunct in severe mucocutaneous pemphigus vulgaris with prior avascular necrosis and chronic kidney disease.Frontiers in medicine · 2026Article
- A Rare Case of Dupilumab Monotherapy in Pemphigoid Nodularis and a Comprehensive Literature Review.Cureus · 2025Article
- Rare Coexistence of Pemphigus Vulgaris and Eosinophilic Esophagitis: A Report of Two Cases.Clinical case reports · 2025Article
- Complete Resolution of Atypical Paraneoplastic Pemphigus Following Treatment With Dupilumab.Cureus · 2025Article
- JAK-STAT pathway, type I/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid.Frontiers in immunology · 2025Review
- Dupilumab as Immunomodulatory Rescue for Severe Recalcitrant Pemphigus Vulgaris: A Case Report and Literature Review.Clinical, cosmetic and investigational dermatology · 2025Article
- Cytokine profiling reveals HLA-linked Th2 and Th17 driven immune activation in pemphigus vulgaris patients and genetically susceptible healthy controls.Frontiers in immunology · 2024Article
- Dupilumab Combined with Glucocorticoids in the Treatment of Pemphigus Vegetans: Case Report.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.